ReviewDrugs & aging1998
Drug dosage in the elderly. Is it rational?
Review in Drugs & aging, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib.Clinical pharmacokinetics · 2003Trial
- Medication errors among elderly in-patients at an urban national referral hospital in Tanzania: Prevalence and patient profiles in a low-resource setting.African health sciences · 2026Article
- Effects of Malnutrition on the Incidence and Worsening of Frailty in Community-Dwelling Older Adults with Pain.Nutrients · 2025Article
- Utilizing Physiologically Based Pharmacokinetic Models to Support Rational Medication in Chinese Elderly Population.Drug design, development and therapy · 2025Article
- Epigenetic regulation of drug metabolism in aging: utilizing epigenetics to optimize geriatric pharmacotherapy.Pharmacogenomics · 2024Review
- Aging and Cardiovascular Disease: Current Status and Challenges.Reviews in cardiovascular medicine · 2022Review
- Biological determinants impact the neurovascular toxicity of nicotine and tobacco smoke: A pharmacokinetic and pharmacodynamics perspective.Neurotoxicology · 2022Review
- A Neuroscience Primer for Integrating Geroscience With the Neurobiology of Aging.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Article
- Immunosuppression Considerations for Older Kidney Transplant Recipients.Current transplantation reports · 2021Article
- Prescribing medicines to older people-How to consider the impact of ageing on human organ and body functions.British journal of clinical pharmacology · 2020Review
- The agitated older adult in the emergency department: a narrative review of common causes and management strategies.Journal of the American College of Emergency Physicians open · 2020Review
- A precision medicine approach to pharmacological adjuncts to extinction: a call to broaden research.Psychopharmacology · 2019Review
- Age dependence of spleen- and muscle-corrected hepatic signal enhancement on hepatobiliary phase gadoxetate MRI.European radiology · 2016Article
- Drug-induced falls in older persons: is there a role for therapeutic drug monitoring?Therapeutic advances in drug safety · 2016Article
- A rare cause of hypoactive delirium.BMJ case reports · 2014Article
- Nicotine pharmacokinetics in rats is altered as a function of age, impacting the interpretation of animal model data.Drug metabolism and disposition: the biological fate of chemicals · 2014Article
- Physiological Changes in Older Adults and Their Effect on Diabetes Treatment.Diabetes spectrum : a publication of the American Diabetes Association · 2014Article
- Treating the elderly diabetic patient: special considerations.Diabetes, metabolic syndrome and obesity : targets and therapy · 2014Review
- Severity and management of drug-drug interactions in acute geriatric patients.Drugs & aging · 2013Article
- The combination of stem cell factor and granulocyte-colony stimulating factor for chronic stroke treatment in aged animals.Experimental & translational stroke medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacotherapy in the elderly requires an understanding of the age-dependent changes in function and composition of the body. Aging is characterised by a progressive loss of functional capacities of most if not all organs, a reduction in response to receptor stimulation and homeostatic mechanisms, and a loss of water content and an increase of fat content in the body. The most important pharmacokinetic change in old age is a decrease in the excretory capacity of the kidney; in this regard, the elderly should be considered as renally insufficient patients. The decline in the rate of drug metabolism with advancing age is less marked. In addition, the volume of distribution and the oral bioavailability of drugs may be changed in the elderly compared with younger individuals. Average dosage adjustments for the aged can be derived from simple equations and mean pharmacokinetic parameters from older and younger adults. However, these average dose adjustment factors neglect the large variation in the decline in organ functions among the elderly. Individual dose adjustment factors can be obtained from the drug clearance in a particular patient, where clearance/fractional bioavailability (CL/f) may be calculated from the area under the plasma concentration-time curve (AUC) of the drug in question. Using pharmacokinetic guidelines for dose adjustments, the same plasma drug concentrations result in elderly as in younger adults. However, we are frequently confronted with pharmacodynamic changes in old age which alter the sensitivity to drugs, irrespective of changes in drug disposition. For instance, the sensitivity of the cardiovascular system to beta-adrenergic agonists and antagonists decreases in old age and the incidence of orthostatic episodes in response to drugs that lower blood pressure is increased. The CNS is especially vulnerable in the elderly; agents that affect brain function (anaesthetics, opioids, anticonvulsants, psychotropic drugs) must be used very cautiously in this age group. The increased responsiveness to drugs in the elderly renders the measurement of drug plasma concentrations an attractive method to monitor pharmacotherapy in this age group. Sensitive technology to quantitatively determine plasma drug concentrations is available. However, optimal therapeutic plasma concentrations have not been established for most drugs in the elderly. Investigations concerning drug pharmacokinetic-pharmacodynamic relationships in the aged are an important area of future work in clinical pharmacology.
Indexed as
Identifiers
9829164What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.